18 studies found for:    bavituximab
Show Display Options
Rank Status Study
1 Completed Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab;   Drug: Gemcitabine
2 Completed A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bavituximab
3 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
4 Terminated Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Conditions: Prostate Cancer;   Prostatic Neoplasms
Intervention: Drug: Cabazitaxel plus bavituximab
5 Completed Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Paclitaxel / Carboplatin;   Drug: bavituximab
6 Recruiting A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
Condition: Stage II and III Rectal Adenocarcinoma
Interventions: Radiation: Radiation Therapy;   Drug: Bavituximab;   Drug: Capecitabine
7 Completed Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Condition: Non-small-cell Lung Cancer
Intervention: Drug: Docetaxel plus bavituximab or placebo
8 Completed Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection
Condition: Hepatitis C
Interventions: Drug: Bavituximab;   Drug: Pegylated interferon (PEG-IFN)
9 Completed Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: bavituximab plus paclitaxel and carboplatin
10 Recruiting Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Conditions: Hepatocellular Carcinoma;   Liver Cancer
Intervention: Drug: bavituximab and sorafenib
11 Active, not recruiting Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: HER2-negative Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: paclitaxel;   Biological: bavituximab;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Recruiting Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Bavituximab
13 Completed Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
Condition: Tumors
Intervention: Drug: Bavituximab
14 Completed Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
Conditions: Hepatitis C Virus;   Hiv Infections
Intervention: Drug: bavituximab
15 Completed Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer
Condition: Carcinoma Breast Stage IV
Intervention: Drug: Bavituximab
16 Recruiting A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
Condition: Melanoma
Interventions: Drug: Arm A-Bavituximab with Ipilimumab;   Drug: Arm B-Ipilimumab
17 Completed Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C
Intervention: Drug: Bavituximab
18 Completed Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C
Condition: Hepatitis C
Intervention: Drug: bavituximab

Indicates status has not been verified in more than two years